Abstract: Disclosed are compounds of general formula (I): wherein R1, R2, A, X, Y and Z are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds and the use of the compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

Abstract: A wound dressing including a nonwoven absorbent layer including a layer of fabric comprising gel-forming fibers. The absorbent layer is gathered in a longitudinal direction by stitching through the layer of fabric using one or more resilient threads or yarns and an inelastic thread or yarn. The resilient and inelastic threads or yarns gather the layer of fabric so that the layer of fabric in use is configured to maintain close conformability with a wound during movement, and to elongate by 35% to 85% and then recover.

Abstract: A closable sanitary napkin system that is secured once rolled or closed by flaps attached towards one end. The flaps remain in contact with the bottom of the napkin until the time of disposal when they are pulled out and used to secure the napkin closed. The napkin could also have a pattern or image printed on the bottom surface to obscure any contents of the napkin.

Abstract: A sensor system for detecting a property of or within an absorbent article may comprise an absorbent article and a sensor. The absorbent article may comprise a garment-facing layer and an absorbent assembly. The sensor may be disposed in and/or on the absorbent article. The sensor may be separable from the absorbent article. The sensor may be configured to sense a change in condition within the absorbent article.

Abstract: An absorbent article includes a liquid permeable, apertured topsheet, a liquid impermeable backsheet, an absorbent core disposed at least partially intermediate the topsheet and the backsheet, and an acquisition material disposed at least partially intermediate the topsheet and the absorbent core. The acquisition material has a caliper in the range of about 2.5 mm to about 10 mm, according to the Caliper Test, and an Air Permeability in the range of about 5,000 l/m2/s to about 11,000 l/m2/s, according to the Air Permeability Test. The acquisition material has a first surface, a second surface, and a plurality of three-dimensional features extending outwardly from the first surface or the second surface.

Abstract: Provided herein are inhibitors of protein arginine deiminases (PADs), pharmaceutical compositions comprising said the compounds, and methods for using the compounds for the treatment of diseases.

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.

Abstract: This invention relates to the large-scale production of psilocybin for use in medicine. Move particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A device holder (20) that holds a transfer device (800) is provided on a stage (10). The device (800) includes a first connector (810) to which a first container (910) is connectable, a second connector (820) to which a second container (950) is connectable, and a connection port (850) to which a syringe (980) is connectable. The stage (10) can be turned to a first turning position where the first connector (810) is located higher than the second connector (820) and a second turning position where the second connector (820) is located higher than the first connector (810). A second container holder (50) that holds the second container (950) coaxially with the second connector (820) turns together with the stage (10) and can be linearly moved along a direction of an axis of the second connector (820).

Abstract: The invention provide novel pyrimidine derivatives and analogs having inhibitory activities towards certain tyrosine kinases, e.g., Bruton's tyrosine kinase (Btk) and/or Focal adhesion kinase (FAK), extracellular signal-regulated kinase (ERK), pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by such by tyrosine kinases, e.g., cancers, tumors, fibrosis, inflammatory diseases, autoimmune diseases, diabetes, or immunologically mediated diseases.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.

Abstract: An absorbent article may include a top sheet that is liquid-permeable, a back sheet that is liquid-impermeable, and an absorbent body situated between the top sheet and the back sheet in a thickness direction. At least one of the top sheet and the back sheet may include a synthetic resin sheet that includes a synthetic resin component and an oxidative decomposer comprising a mixture of a carboxylate and a rare earth compound. The synthetic resin sheet may contain the oxidative decomposer in a mass ratio such that a decomposition rate index (Di), as determined by formula (1), is 7.8 or less: Di=Br×Sa??(1) where Br represents a mass ratio (g/g) of the oxidative decomposer with respect to the synthetic resin component, and Sa represents a specific surface area (cm2/g) of the synthetic resin sheet.

Abstract: Disclosed is an array 1 of wearable articles 20, each article comprising a main body 38 and a ring-like elastic belt 40 comprising a front belt and a back belt wherein at least the front belt or the back belt is an elastic member having an elastic member width in the transverse direction and a non-elastic region; wherein a first elastic member of a first article comprises a first non-elastic region; a second elastic member of a second article comprises a second non-elastic region; a third elastic member of a third article comprises a third non-elastic region; wherein the elastic member width of the first, second, and third elastic members are the same; and the first, second, and third non-elastic regions are different from each other.

Abstract: A system for connection to a catheter to aspirate clot from the vasculature of a patient includes a vacuum console and a canister assembly which can be removably mounted in a mounting region of the vacuum console. The canister assembly includes a clear canister with an interior and an open top. A lid is removably attachable over the open top of the clear canister, and the clear canister has a vacuum port and a pressure sensing port each formed in a wall of the canister. The vacuum port aligns with a vacuum connector on the enclosure and the pressure sensing port aligns with a pressure sensing connector on the enclosure when the canister assembly is mounted on the mounting region of the vacuum console. The clear canister has a filter plate configured to be suspended in the interior of the clear canister at a location mid-way between the open top and a bottom to separate clot from blood as they are aspirated from the catheter.

Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

Abstract: Provided are a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist, crystalline forms of a hydrochloride of the diaminopyrimidine derivative, and processes for preparing the same.

Abstract: An absorbent article comprising a topsheet, a backsheet joined to the topsheet, and an absorbent core positioned intermediate the topsheet and the backsheet and comprising a core absorbent material, in which the core absorbent material comprises superabsorbent polymers with a bio-based content from about 5% to about 100% using ASTM D6866-10, method B and the absorbent article comprises a polyolefin content of at least about 90% by weight, based on a total weight of the absorbent article excluding the core absorbent material.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.